Development of an ultra-sensitive detection method for minimal residual disease of melanoma using whole genome analysis of blood

초록

Development of an ultra-sensitive detection method for minimal residual disease of melanoma using whole genome analysis of blood Jun Hyeok Lim1, Jeong-Seon Ryu1, Ji Won Byun2, Jongsuk Chung3, Hyun-Tae Shin2,4,* 1Department of Internal Medicine, Inha University Hospital, Incheon, Republic of Korea.. 2Department of Dermatology, Inha University Hospital, Incheon, Republic of Korea. 3Gencurix Inc., Seoul, Republic of Korea. 4Research Center for Controlling Intercellular Communication (RCIC), Inha University School of Medicine, Incheon, Republic of Korea. Melanoma is known for its high risk of recurrence and metastasis, often leading to severe outcomes. Detecting minimal residual disease (MRD) after primary treatment is essential to prevent recurrence and improve patient prognosis. However, current detection methods lack the sensitivity needed for accurate MRD monitoring in melanoma patients. We have developed an ultra-sensitive method for detecting melanoma MRD using whole-genome analysis of circulating cell-free DNA (cfDNA) in blood samples. This approach utilizes advanced sequencing technologies to identify tumor-specific mutations and structural variations within cfDNA, offering a comprehensive profile of residual cancer cells. We validated this technique through cancer cell-line mix experiments and clinical samples from both melanoma and lung cancer patients. By enabling the detection of potential recurrences earlier than traditional imaging or blood markers, this method holds promise for significantly improving patient outcomes. Moreover, this technology could be applicable across various cancer types where cfDNA-based monitoring is advantageous. ? Category: Skin tumor ? Presentation Type: Oral and/or Poster